MAGE-A3/HPV 16 peptide vaccines for head and neck cancer

Abstract

The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the head and neck (SCCHN) using the Trojan antigens and immunogenic compositions of the present invention.

1 . A isolated polypeptide comprising amino acids 1-35 of SEQ ID NO:15.  
     
     
         2 . A isolated polypeptide comprising amino acids 1-47 of SEQ ID NO:17.  
     
     
         3 . A isolated polypeptide comprising amino acids 1-21 of SEQ ID NO:19.  
     
     
         4 . A isolated polypeptide comprising amino acids 1-43 of SEQ ID NO:22.  
     
     
         5 . The isolated polypeptide of  claim 3 , wherein X cysteine or aminobutyric acid.  
     
     
         6 . The isolated polypeptide of  claim 4 , wherein X 6 , X 30 , X 31 , and X 33  are each independently cysteine or aminobutyric acid.  
     
     
         7 . An immunogenic composition comprising a polypeptide of  claim 2  or  4 , and a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         8 . An immunogenic composition comprising the polypeptide of claims  2  and  4 , and a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         9 . A method of generating an immune response in a subject comprising administering a polypeptide comprising amino acids 1-47 of SEQ ID NO:17 to a subject in an amount sufficient to induce an immune response in said subject.  
     
     
         10 . A method of generating an immune response in a subject comprising administering a polypeptide comprising amino acids 1-43 of SEQ ID NO:22, wherein X 6 , X 30 , X 31  and X 33  are each independently cysteine or aminobutyric acid, to a subject in an amount sufficient to induce an immune response in said subject.  
     
     
         11 . A method of generating an immune response in a subject comprising administering (a) a polypeptide comprising amino acids 1-47 of SEQ ID NO:17 and (b) a polypeptide comprising amino acids 1-43 of SEQ ID NO:22, wherein X 6 , X 30 , X 31  and X 33  are each independently cysteine or aminobutyric acid, to a subject in an amount sufficient to induce an immune response in said subject.  
     
     
         12 . The method of  claim 9  or  10 , wherein said polypeptide is administered in conjunction with a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         13 . The method of  claim 11 , wherein said polypeptides are administered in conjunction with a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         14 . The method of  claim 9  or  10 , wherein said polypeptide is administered in an amount of between about 100 ug and about 1.5 mg.  
     
     
         15 . The method of  claim 11 , wherein said polypeptides are administered in a combined amount of between about 100 ug and about 1.5 mg.  
     
     
         16 . The method of  claim 9  or  10 , wherein said polypeptide is administered in an amount of about 1 mg.  
     
     
         17 . The method of  claim 11 , wherein said polypeptides are administered in a combined amount of about 1 mg.  
     
     
         18 . The method of  claim 9  or  10 , wherein said polypeptide is co-administered with montanide, in an amount of between about 0.5 and 1.5 mL, and GM-CSF, in an amount of between about 50 and 150 ug/m 2 .  
     
     
         19 . The method of  claim 11 , wherein said polypeptides are co-administered with montanide, in an amount of between about 0.5 and 1.5 mL, and GM-CSF, in an amount of between about 50 and 150 ug/m 2 .  
     
     
         20 . A method of treating squamous cell carcinoma of the head and neck (SCCHN) comprising administering to a subject in need of such treatment a therapeutically-effective amount of a polypeptide comprising amino acids 1-47 of SEQ ID NO:17.  
     
     
         21 . A method of treating SCCHN comprising administering to a subject in need of such treatment a therapeutically-effective amount of a polypeptide comprising amino acids 1-43 of SEQ ID NO:22, wherein X 6 , X 30 , X 31  and X 33  are each independently cysteine or aminobutyric acid.  
     
     
         22 . A method of treating SCCHN comprising administering to a subject in need of such treatment a therapeutically-effective amount of (a) a polypeptide comprising amino acids 1-47 of SEQ ID NO:17 and (b) a polypeptide comprising amino acids 1-43 of SEQ ID NO:22, wherein X 6 , X 30 , X 31  and X 33  are each independently cysteine or aminobutyric acid.  
     
     
         23 . The method of  claim 20  or  21 , wherein said polypeptide is co-administered with a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         24 . The method of  claim 22 , wherein said polypeptides are co-administered with a pharmaceutically acceptable carrier, diluent or adjuvant.  
     
     
         25 . The method of  claim 20  or  21 , wherein said polypeptide is administered in an amount between about 100 ug and about 1.5 mg.  
     
     
         26 . The method of  claim 22 , wherein said polypeptides are administered in a combined amount of between about 100 ug and about 1.5 mg.  
     
     
         27 . The method of  claim 20  or  21 , wherein said polypeptide is administered in an amount of about 1 mg.  
     
     
         28 . The method of  claim 22 , wherein said polypeptides are administered in a combined amount of about 1 mg.  
     
     
         29 . The method of  claim 20  or  21 , wherein said polypeptide is co-administered with montanide, in an amount of between about 0.5 and 1.5 mL, and GM-CSF, in an amount of between about 50 and 150 ug/m 2 .  
     
     
         30 . The method of  claim 22 , wherein said polypeptides are co-administered with montanide, in an amount of between about 0.5 and 1.5 mL, and GM-CSF, in an amount of between about 50 and 150 ug/m 2 .  
     
     
         31 . An expression vector comprising an isolated polynucleotide molecule encoding amino acids 1-35 of SEQ ID NO:15.  
     
     
         32 . An expression vector comprising an isolated polynucleotide molecule encoding amino acids 1-47 of SEQ ID NO:17.  
     
     
         33 . An expression vector comprising an isolated polynucleotide molecule encoding amino acids 1-21 of SEQ ID NO:19.  
     
     
         34 . An expression vector comprising an isolated polynucleotide molecule encoding amino acids 1-43 of SEQ ID NO:22.  
     
     
         35 . A host cell comprising an expression vector of  claim 31 .  
     
     
         36 . A host cell comprising an expression vector of  claim 32 .  
     
     
         37 . A host cell comprising an expression vector of  claim 33 .  
     
     
         38 . A host cell comprising an expression vector of  claim 34 .  
     
     
         39 . A method of preparing a polypeptide comprising amino acids 1-35 of SEQ ID NO:15, comprising culturing the host cell of  claim 35  under conditions promoting expression of said polypeptide and recovering said polypeptide from the cell culture.  
     
     
         40 . A method of preparing a polypeptide comprising amino acids 1-47 of SEQ ID NO:17, comprising culturing the host cell of  claim 36  under conditions promoting expression of said polypeptide and recovering said polypeptide from the cell culture.  
     
     
         41 . A method of preparing a polypeptide comprising amino acids 1-21 of SEQ ID NO:19, comprising culturing the host cell of  claim 37  under conditions promoting expression of said polypeptide and recovering said polypeptide from the cell culture.  
     
     
         42 . A method of preparing a polypeptide comprising amino acids 1-43 of SEQ ID NO:22, comprising culturing the host cell of  claim 38  under conditions promoting expression of said polypeptide and recovering said polypeptide from the cell culture.